Ablynx NV [Euronext Brussels and Nasdaq: ABLX] has announced that results from its Phase III HERCULES study of caplacizumab have been selected as one of only six abstracts for oral presentation in the late-breaking abstracts session at the 59th Annual Meeting of the American Society of Hematology (ASH) taking place in Atlanta, GA, on 12 December 2017.
Caplacizumab is Ablynx’s wholly-owned anti-von Willebrand factor (vWF) Nanobody® being developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Positive topline results from the Phase III HERCULES study, meeting primary and two key secondary endpoints, were announced on 2 October 2017.
The abstract (LBA-1), “Results of the Randomized, Double-Blind, Placebo-Controlled, Phase III HERCULES study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura”, will be presented by Professor Marie Scully, M.D., Department of Haematology, University College London Hospitals NHS Trust, London, UK.
The abstract is available at https://ash.confex.com/ash/2017/webprogram/Paper109057.html and will be included in the 8 December online issue of Blood.
Commenting on today’s announcement, Dr Edwin Moses, CEO of Ablynx, said: “We are very pleased that our positive Phase III HERCULES data have been accepted for this presentation at the world’s leading hematology conference, the 2017 ASH Annual Meeting in Atlanta, USA. The data confirm the significant potential of caplacizumab for patients with aTTP for whom there is currently no approved therapeutic drug available.”
